RICARDO ATTAR, Ph.D.
ONCOLOGY TRANSLATIONAL RESEARCH
Ricardo Attar, Ph.D. is Vice President, Oncology Translational Research, for the Janssen Pharmaceutical Companies of Johnson & Johnson. In this position, he leads the Translational Research (TR) group, including the Hematologic Malignancies, Lung Cancer, Prostate Cancer and Immuno-Oncology Therapy TR teams. The Oncology TR group is responsible for all clinical biomarker and translational medicine strategies for compounds in developing within the Oncology Therapeutic Area pipeline. The team also works to advance prevention and disease interception strategies across oncology.
Prior to his current appointment, Ricardo led the Hematologic Malignancies Discovery strategy and team. Under his leadership, the team delivered 10 new molecular entities, including T-cell redirecting bi-specific antibodies for the treatment of multiple myeloma (MM), acute myeloid leukemia (AML) and diffuse large B cell lymphoma (DLBCL), as well as chimeric antigen receptor T-cell therapies for MM and small molecule inhibitors for DLBCL and AML.
Ricardo joined Janssen in 2008 after spending 15 years in the Oncology Discovery department at Bristol Myers Squibb. During this time, he led several programs to their nomination as clinical candidates.
Ricardo received his doctorate in Molecular Biology from the University of Buenos Aires, Argentina, and his postdoctoral training at Cold Spring Harbor Laboratory in New York.